Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Synexus Clinical Research Midco No 1 Limited, a prominent player in the clinical research industry, is headquartered in Great Britain. Established in 1999, the company has made significant strides in advancing clinical trials across various therapeutic areas, including oncology, cardiology, and neurology.
With a strong operational presence in Europe and beyond, Synexus is renowned for its patient-centric approach and extensive network of clinical trial sites. The company offers a unique blend of services, including patient recruitment, site management, and data collection, which distinguishes it in a competitive market.
Recognised for its commitment to quality and innovation, Synexus has achieved notable milestones, positioning itself as a trusted partner for pharmaceutical and biotechnology companies seeking to expedite their research and development processes.
No reported emissions data is available for Synexus Clinical Research Midco No 1 Limited yet.
Synexus Clinical Research Midco No 1 Limited, headquartered in Great Britain, currently does not report specific carbon emissions data for the most recent year, as indicated by the absence of emissions figures. The company is a current subsidiary of Thermo Fisher Scientific Inc., and any climate commitments or emissions data may be inherited from this parent organization.
As part of its corporate family relationship, Synexus is aligned with the climate initiatives and targets set by Thermo Fisher Scientific Inc. This includes participation in the Science Based Targets initiative (SBTi) and other sustainability frameworks, although specific reduction targets for Synexus itself have not been detailed.
While no absolute emissions numbers are available, the commitment to sustainability and climate action is evident through the cascading of initiatives from Thermo Fisher Scientific Inc. This includes adherence to industry-standard climate terminology and practices, reflecting a broader commitment to reducing carbon footprints across its operations.
In summary, while Synexus Clinical Research Midco No 1 Limited does not provide specific emissions data or reduction targets, it is positioned within a corporate structure that prioritises climate commitments and sustainability initiatives through its parent company, Thermo Fisher Scientific Inc.
No climate goals have been disclosed for Synexus Clinical Research Midco No 1 Limited yet.
No scope 3 category breakdown has been disclosed yet.


No peer comparison is available for Synexus Clinical Research Midco No 1 Limited yet.
PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more